Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine: A Review of 60 Cases

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Thrombotic thrombocytopenic purpura, a life-threatening multisystem disease, has been infrequently associated with use of ticlopidine, a platelet anti-aggregating agent.

Purpose

To review 60 cases of ticlopidine-associated thrombotic thrombocytopenic purpura.

Data Sources

Medical records, published case reports, and case reports submitted to the U.S. Food and Drug Administration.

Study Selection

Instances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified.

Data Synthesis

Ticlopidine had been prescribed for less than 1 month in 80% of the patients, and normal platelet counts had been found within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients. Mortality rates were higher among patients who were not treated with plasmapheresis than among those who underwent plasmapheresis (50% compared with 24%; P < 0.05).

Conclusions

Ticlopidine use may be associated with the development of thrombotic thrombocytopenic purpura, usually within 1 month of initiation of therapy. The onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to predict, despite close monitoring of platelet counts.

Related Topics

    loading  Loading Related Articles